Clinical Trial Update: Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase I clinical trial evaluating CY-219 CAR-T cell therapy for relapsed/refractory B-cell lymphoma; not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Or Refractory B-cell Lymphoma

Drugs mentioned

• CY-219 CAR-T Cell Injection

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed/Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Status: NOT_YET_RECRUITING